Delivery Order SPE2DB25D3306-SPE2DB25FUCPH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,322.71 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's pharmaceutical supply relationship with DLA. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $5,053.83 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,796.45 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $27,184.05 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. XELJANZ XR is a...
- The Defense Logistics Agency awarded a delivery order valued at $11,428.25 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count unit of use packaging) on August 29, 2025, with completion scheduled for September 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical supply transaction for federal medical procurement. The work will be performed at AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a $11,537.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on July 1, 2025, with completion targeted for July 2, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered...
- The Defense Logistics Agency awarded a delivery order valued at $10,970.04 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-competitive set-aside contract. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major...
- The Defense Logistics Agency awarded a $28,849.31 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) with an ultimate completion date of June 20, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,198.50 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count) under a firm fixed price contract type. This award, issued on July 28, 2025, with completion targeted for July 29, 2025, represents a small-value pharmaceutical delivery to support federal medical procurement needs. The contract carries no set-aside designation, indicating it was competitively awarded through open procurement channels. AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $8,137.72 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement supporting federal pharmaceutical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- SPE2DB25D3306Indefinite Delivery Contract
- SPE2DB25D3306-SPE2DB25FUCPHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,280.00 to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price, competitively awarded contract (no set-aside used) was executed on August 12, 2025, with an ultimate completion date of August 13, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's extensive pharmaceutical supply relationship with the federal government. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including customers such as the Defense Health Agency and U.S. Coast Guard. XELJANZ XR is a rheumatoid arthritis treatment, demonstrating the company's role in delivering specialized medications to federal healthcare systems through this strategic vendor partnership.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/12/25 |